Key Highlights
- ORIC Pharmaceuticals (NASDAQ:ORIC) recorded a loss of USD 48.1 million for the third quarter, which is USD 0.44 per share, versus USD 32.6 million or USD 0.33 per share twelve months back.
- Development outlays climbed to USD 43.4 million from USD 28.8 million, with outside rinzimetostat costs accounting for USD 21.2 million compared with USD 5.6 million before.
- The company held USD 345.4 million across cash, equivalents and investments at September 30, 2026, a balance it expects to sustain operations into the second half of 2028.
- Losses for nine months totalled USD 125.3 million, the accumulated Deficit stands at USD 817.6 million, and at-the-market issuance generated approximately USD 59.9 million across that period.
Rinzimetostat Expenses Widen the Quarterly Deficit
ORIC Pharmaceuticals (NASDAQ:ORIC) submitted its quarterly filing on November 16, 2026. Headquartered in South San Francisco, this clinical-stage biotech targets cancers that develop resistance to treatment, and its two lead Assets are rinzimetostat, an oral PRC2 inhibitor for prostate cancer, and enozertinib, a brain-penetrant compound for EGFR-mutated lung cancer. Operating losses widened to USD 51.6 million from USD 36.7 million, so the Bottom Line deteriorated by USD 15.5 million to USD 48.1 million. A USD 3.5 million contribution from interest and other income cushioned the result, though it was lower than the USD 4.1 million recorded a year earlier. The nine-month loss reached USD 125.3 million against USD 99.0 million.
Himalayas-1 Launch and Enozertinib Readout Shift the Cost Mix
Research and development spend grew by USD 14.6 million to USD 43.4 million, principally driven by outside rinzimetostat expenditure of USD 21.2 million. Enozertinib costs moderated to USD 7.6 million from USD 9.0 million because Manufacturing and clinical activity shifted in timing. In July 2026, ORIC began Himalayas-1, a worldwide Phase 3 trial pairing rinzimetostat with darolutamide in metastatic castration-resistant prostate cancer, and Bayer supplies the darolutamide without charge. October brought enozertinib results from untreated patients with atypical EGFR mutations, showing confirmed systemic responses in 84% of patients and confirmed intracranial responses in 70%. Overhead, meaning general and administrative spending, crept up to USD 8.2 million from USD 7.9 million.
Liquidity Composition, Share Sales and the Path Into 2028
Quarter-end Liquidity comprised USD 33.8 million of cash and equivalents, USD 227.5 million of short-term investments and USD 84.0 million of long-term investments, adding up to USD 345.4 million. Over nine months operating cash outflow amounted to USD 106.0 million, versus USD 88.5 million the prior year. Using its at-the-market facility, the company placed 4,698,400 shares at a weighted average USD 12.96, raising roughly USD 59.9 million, with no proceeds in the third quarter alone. About 103.9 million shares were outstanding on November 9, 2026, along with 4,463,636 pre-funded warrants still open. In October, Cancer Research UK agreed to finance development of ORIC-259, which targets CIP2A.
Where Things Stand
The filing depicts rising spend as rinzimetostat moves into Phase 3, with the quarterly loss up almost half, yet management still anticipates funding into the second half of 2028. ORIC Pharmaceuticals (NASDAQ:ORIC) generates no product Revenue and acknowledges that considerable further Capital will be required to complete development and reach commercial sales. Key checkpoints include Himalayas-1 enrolment, mid-2027 enozertinib data in first-line lung cancer carrying exon 20 insertions and any capital raised beyond the existing at-the-market program.






Please wait processing your request...